Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $17
Credit Suisse analyst Judah Frommer maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Outperform and lowers the price target from $26 to $17.
Acumen Pharmaceuticals FY21 EPS $(5.02) Up From $(17.48) YoY
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(5.02) per share. This is a 71.28 percent increase over losses of $(17.48) per share from the same period last year.
Earnings Scheduled For March 28, 2022
Companies Reporting Before The Bell
• LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning trading, 87 companies set new 52-week lows.
Acumen Announces First Patient Dosed In A Phase 1 Clinical Trial Of ACU193, A Monoclonal Antibody That Selectively Targets Toxic Aβ Oligomers For The Treatment Of Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced dosing of the first patient in
72 Biggest Movers From Yesterday
Gainers
Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.